Showing results (81-90 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|December 10, 2023
RPTOR mutation: a novel predictor of efficacious immunotherapy in melanomaYanfang Jiang, Xintong Hu, Zhouyu Wang, et al.
Investigational New Drugs|November 16, 2023
Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification : Immunoneoadjuvant therapy of gastric cancerGuoliang Yao, Jianyong Yuan, Qianqian Duan, et al.
Investigational New Drugs|November 7, 2023
The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell linesJulia Schnoell, Carmen Sparr, Sega Al-Gboore, et al.
Investigational New Drugs|August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational studyRebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, et al.
Investigational New Drugs|October 19, 2023
Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese expertsYoshitaka Honma, Masafumi Ikeda, Susumu Hijioka, et al.
Investigational New Drugs|October 13, 2023
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutationYujie Cui, Jinlong Liang, Xiyun Kang, et al.
Investigational New Drugs|September 29, 2023
Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoidMiao Liu, Maoye Yuan, Wei Sun, et al.
Investigational New Drugs|May 11, 2002
Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analoguesJennette A Sakoff, Stephen P Ackland, Monique L Baldwin, et al.
Investigational New Drugs|May 11, 2002
Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot studyN Tsavaris, C Kosmas, M Vadiaka, et al.
Investigational New Drugs|November 27, 2002
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancySherry Morgan-Meadows, James P Thomas, Daniel Mulkerin, et al.
Pageof 372